Flexion Therapeutics Inc (FLXN) Given a $40.00 Price Target at Cantor Fitzgerald
Flexion Therapeutics Inc (NASDAQ:FLXN) has been given a $40.00 target price by Cantor Fitzgerald in a research report issued on Monday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 104.19% from the company’s current price.
Other research analysts have also issued reports about the company. Royal Bank of Canada set a $44.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, March 26th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Janney Montgomery Scott reiterated a “buy” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Wells Fargo & Co reiterated an “outperform” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 25th. Finally, BMO Capital Markets reiterated a “positive” rating and issued a $33.00 target price on shares of Flexion Therapeutics in a report on Tuesday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $29.23.
Flexion Therapeutics (NASDAQ:FLXN) traded up 2.08% on Monday, hitting $19.59. The stock had a trading volume of 982,188 shares. Flexion Therapeutics has a 52-week low of $10.60 and a 52-week high of $29.41. The company’s market cap is $622.12 million. The firm’s 50-day moving average is $22.71 and its 200-day moving average is $20.56.
Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.02. Equities research analysts anticipate that Flexion Therapeutics will post ($3.72) earnings per share for the current fiscal year.
In other news, insider Neil Bodick sold 5,000 shares of Flexion Therapeutics stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $20.41, for a total transaction of $102,050.00. Following the sale, the insider now owns 50,937 shares in the company, valued at $1,039,624.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Frederick W. Driscoll sold 3,000 shares of Flexion Therapeutics stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the sale, the chief financial officer now owns 10,777 shares in the company, valued at approximately $247,871. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,000 shares of company stock worth $407,950. 18.00% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the company. State Street Corp boosted its stake in Flexion Therapeutics by 111.8% in the first quarter. State Street Corp now owns 829,254 shares of the specialty pharmaceutical company’s stock worth $22,316,000 after buying an additional 437,648 shares during the period. Kingdon Capital Management L.L.C. boosted its stake in Flexion Therapeutics by 29.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 1,379,486 shares of the specialty pharmaceutical company’s stock worth $26,238,000 after buying an additional 311,865 shares during the period. Novo A S boosted its stake in Flexion Therapeutics by 27.3% in the fourth quarter. Novo A S now owns 1,397,718 shares of the specialty pharmaceutical company’s stock worth $26,585,000 after buying an additional 300,000 shares during the period. Pictet Asset Management Ltd. purchased a new stake in Flexion Therapeutics during the first quarter worth approximately $7,323,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Flexion Therapeutics during the fourth quarter worth approximately $4,755,000. Institutional investors and hedge funds own 62.25% of the company’s stock.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.